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The MYB family of transcription factors has three members: A-myb (MYBL1), B-myb (MYBL2), and c-myb (MYB). Disruption of the c-myb locus in mice results in embryonic lethality at embryonic day 15, primarily due to defective erythropoiesis in the fetal liver (4) . A role for c-myb in adult hematopoiesis has been shown more recently using several conditional knockout (KO) and mutant mouse models. In adult thymocytes and B lymphocytes, disruption of c-myb blocks development at the DN3 and prepro B stages, respectively (5) (6) (7) (8) . c-myb expression is also required for erythropoiesis, myelopoiesis, and the development and maintenance of HSCs (9) (10) (11) (12) , underscoring the importance of this gene within the entire hematopoietic compartment.
B-myb-null mutant mice die in utero at days 4-6.5 of gestation due to defects in inner cell mass formation (13) , which precludes the study of this gene in hematopoiesis. In this paper, we describe the effects of conditional disruption of B-myb in adult hematopoietic cells. Loss of B-myb leads to depletion of the HSC pool, resulting in dramatic losses of mature cells in multiple lineages. The effect of B-myb deficiency is autonomous and is associated with defects in HSC cell cycle progression and increased levels of cell death in the myeloid progenitor compartment. Gene expression analysis indicates that B-myb-null LSK + cells differentially express genes that regulate myeloid lineage development and commitment, suggesting that B-myb plays a critical role in regulating HSC and progenitor cell maintenance.
Results
Loss of B-myb Expression Results in Defective Hematopoiesis. In BM, B-myb mRNA is expressed at appreciable levels in the HSC and myeloid progenitor compartments, with the highest levels in the CMP and GMP populations. These levels are in stark contrast to those of mature, lineage + (Lin + ) cells (Fig. 1A) . To determine the role of B-myb in adult hematopoiesis, we generated a conditional B-myb floxed (B-myb F/F ) mouse model ( Fig. 1 B-D ) and crossed this mouse with the Mx1-cre strain (14) . Administration of
Significance
Hematopoiesis is a tightly regulated process by which hematopoietic stem cells (HSCs) give rise to mature cells. The balance between the propensity of HSCs to remain quiescent, to divide and generate more HSCs (self-renewal), or to divide and give rise to mature cells (differentiation) is essential for the longterm maintenance of blood cell formation. Mechanisms underlying cell fate decisions of HSCs are not completely understood. We observed that deletion of the B-myb gene leads to depletion of the HSC pool and losses of mature cells. Our further studies strongly suggest that these effects are due to defects in HSC proliferation and differentiation. We therefore identified B-myb as a critical component of the mechanism that balances self-renewal and differentiation of HSCs.
polyinosinic:polycytidylic acid (pIpC) to B-mybF/F-Cre mice (designated "F/Fcre") resulted in a dramatic loss of cellularity in the BM and spleen ( Fig. 2 A and B) compared with identically treated littermate control (F/F or +/F) animals. Notably, we observed significant decreases in the number of B-and T-lymphoid, erythroid, and myeloid lineage cells, with the myeloid compartment being most profoundly affected in both tissues ( Fig. 2 C and D) . Statistically significant reductions in the number of platelets, total white blood cells, lymphocytes, and neutrophils were also observed in the peripheral blood (PB) of B-myb-deficient F/Fcre animals (Fig. S1 ). These differences resulted in changes in the frequencies of cell types in the spleen and BM (Fig. S2) , as the percentages of B, erythroid, and myeloid cells were altered in the absence of B-myb expression. Although the number of T-lineage (CD3 + ) cells were also decreased in both the BM and spleen, thymocytes and the CD3 + cells in the thymus were not significantly depleted (Fig. 2 C-F) .
A more detailed examination of the HSC and progenitor compartments showed that B-myb-deficient mice have marked decreases in the absolute number of HSCs (Lin (Fig. 2H ) (17) , this difference was not significant. Consistent with the reductions in myeloid progenitors, B-myb-deficient BM also formed fewer colonies in in vitro colony-forming unit (cfu) assays (Fig. 2I) . All of the myeloid lineage colonies that were scored, with the exception of CFU-M, were reduced in number in cultures derived from B-myb-deficient BM. The increased number of CFU-M colonies, although not statistically significant, mirrors the CD11b + Gr1 lo monocytecontaining population whose frequency is increased in B-myb F/Fcre mice (Fig. S2A) . Taken together, these results show that B-myb expression is required for adult hematopoiesis and for the maintenance of HSCs and myeloid progenitor cells.
B-myb-Mediated Defects in the BM Are Autonomous. We next performed noncompetitive BM transplantation assays to determine whether the defect in hematopoiesis was intrinsic to BM. Whole BM was isolated from CD45.2 + control or B-myb-deficient mice and transplanted into lethally irradiated CD45.1 + recipients (Fig. S3A) . pIpC was administered once engraftment was stable (8-10 wk posttransplant) and ∼90% of the PB in the recipients was reconstituted from CD45.2 + donor-derived cells (Fig. 3A ). Mice transplanted with B-myb-deficient BM and treated with pIpC became pancytopenic ( (Fig. S6 ). In contrast, multilineage reconstitution by B-mybdeficient BM was strongly impaired at 4 wk posttransplant, and decreased progressively over time, demonstrating that B-myb is required for the maintenance and self-renewal of HSCs.
B-myb Disruption Leads to Aberrant Cell Cycle Progression of HSCs.
Loss of HSC renewal is often associated with a defect in proliferative control. In their steady-state, HSCs are largely quiescent and enter the cell cycle in response to stimuli that trigger differentiation and lineage commitment (18) . B-myb has been shown to play a role in the cell cycle progression of multiple cell types and is involved in regulating progression through the S and G 2 /M phases (19) (20) (21) (22) (23) (24) (25) . To determine whether loss of B-myb expression led to altered cell cycle kinetics in HSCs, pIpC-treated control and B-myb F/Fcre mice were injected with BrdU and BM was harvested 2 h posttreatment. BrdU incorporation was significantly higher in B-myb-deficient HSCs compared with those of the control, reflecting increases in the fraction of cells in the S and G 2 /M phases (Fig. 4A) . In the myeloid compartments, more subtle but statistically significant increases in the frequencies of cells in the G 2 /M phase were observed as a consequence of B-myb deletion. These studies indicate that loss of B-myb expression alters cell cycle progression predominantly in HSCs, and to a lesser extent, in myeloid progenitors.
Loss of B-myb Increases Cell Death of Myeloid Progenitors. We next determined whether altered cell cycle kinetics in B-myb KO mice resulted in differentiation-associated cell death, which might account for the depletion of HSCs and progenitors, by staining BM from pIpC-treated control and B-myb KO mice with Annexin V. B-myb KO mice did not have increased percentages of apoptotic (Annexin V + DAPI + ) HSCs or MPPs (Fig. 4B) . However, the fraction of apoptotic CMPs, GMPs, and MEPs was higher in B-myb-deficient animals, with the difference in cell death being significant in the GMP population. Interestingly, despite the fact that B-myb-deficient mice have a profound reduction in the number of myeloid progenitors and mature myeloid cells (Fig. 2) , the relative frequency of GMPs was actually increased in these animals (Fig. 4C) . To determine whether the higher percentage of GMPs in the B-myb KO mice resulted from increased differentiation of CMPs and/or proliferation of GMPs, we sorted these populations from control and B-myb F/Fcre mice (16) and plated them in GM-CSF-containing medium in the presence of IFN-α to delete floxed sequences in vitro (12) . Loss of B-myb resulted in lower cell numbers, reflecting an inhibition of both CMP and GMP proliferation (Fig. S7A) . Furthermore, a sharp decrease in the frequency of CD11b + and Gr1 + mature myeloid cells was observed in cultures of CMPs. The frequency of the CD11b + Gr1 hi population in the B-myb F/Fcre GMP cultures was also significantly decreased (Fig. S7B) , suggesting that loss of B-myb affects proliferation and differentiation along the myeloid lineage.
Disruption of B-myb Results in Altered Gene Expression in LSK
+ Cells.
To gain mechanistic insight into the hematological defects in B-myb-deficient mice, we performed a oligonucleotide microarray analysis of the Lin − Sca1 + ckit + (LSK + ) population because the defect in development originates in the HSCs. Comparative analysis and hierarchical clustering identified 438 and 470 genes that were significantly up-and down-regulated, respectively, in the B-myb KO cells (Fig. 5A ). When these gene lists were further analyzed using the ChIP Enrichment Analysis (ChEA) database within ENRICHR (http://amp.pharm.mssm.edu/Enrichr) (26, 27) , considerable overlap was observed with the promoters of genes that are occupied by transcription factors during the control of maintenance, development, and multipotency of HSCs and progenitor cells as well as embryonic stem cells (ESCs) (Dataset S1) (28) (29) (30) (31) (32) (33) (34) . Of these transcription factors, C-MYC and E2F-1 are known to be intricately involved in B-MYB-dependent transcription (22, 25, (35) (36) (37) (38) , whereas others, such as JARID1A, RUNX1 (AML1), TAL1 (SCL), LMO1, and FLI1, are not as well defined with respect to B-MYB transcriptional activation and repression of its targets (25, 39) . In addition to the transcription factors listed above, we also detected an overlap with genes that are targets of C-MYB, which is known to regulate promoters that are both distinct from and common with other members of the MYB family (40, 41) .
We next confirmed the pattern of expression of differentially expressed genes known to be expressed in HSCs that, based on the predicted level of expression in the absence of B-myb, might possibly account for the observed phenotype. Quantitative PCR (qPCR) revealed that the level of cyclin D1 (CCND1), which promotes G 1 /S progression, is increased by approximately eightfold in B-myb-deficient LSK + cells (Fig. 5B) . We also detected a decrease in S/G 2 cyclin, cyclin G2 (CCNG2) expression after B-myb deletion. The dramatic changes in the myeloid progenitor compartment of the B-myb KO mice also prompted us to assess the expression of select genes that govern myeloid lineage development. ID1, GATA2, and CEBPα are transcription factors that regulate HSC development as well as various stages of myeloid lineage commitment (42) . ID1 levels, which normally increase as cells transition to the GMP stage (43) , were elevated in B-myb KO LSK + cells (Fig. 5B) , along with those of CEBPα and to a lesser extent, myeloperoxidase (MPO). Of these, CEBPα is required for the development of CMPs to GMPs (44) . GATA2, on the other hand, was decreased in the absence of B-myb. We also examined the expression pattern of genes that modulate S phase progression and G 2 /M transition, some of which have been implicated in the proliferative defects observed in B-myb-null ESCs (22) . Of the genes analyzed in Fig. S8 , only PLK1 and BIRC5 (survivin) were predicted to be differentially expressed. The expression pattern of these genes does not overlap with B-myb KO ESCs, which might suggest a differential use of target genes in LSK + cells, or, simply reflects a greater accumulation of B-mybdeficient LSK + cells in S phase compared with ESCs (22) . Given that B-myb-null HSCs display a profound engraftment defect, these studies suggest that loss of B-myb induces changes in gene expression that impair self-renewal and results in aberrant lineage commitment.
Discussion
Here, we describe the effect of loss of B-myb during adult hematopoiesis. Our studies show that B-myb-deficient mice are pancytopenic, with dramatic losses in BM and splenic cellularity, have a profound cell-automous defect in HSC repopulation capacity, altered HSC (and to lesser extent of myeloid progenitor) cycling, as well increased apoptosis of myeloid progenitors. Studies have shown that cycling HSCs and those that have recently undergone cell division have profound reductions in their engraftment potential, and that long-term repopulation is dependent on the ability of these cells, or at least a portion of them, to remain in a quiescent state (18) . HSC quiescence is key to maintaining the balance between long-term self-renewal and differentiation. Accordingly, genetic disruption of genes that alter cell division cause BM failure due to HSC exhaustion (45) . Analysis of B-myb-deficient HSCs revealed that significant percentages of cells are in the S and G 2 /M phases. B-myb KO myeloid progenitors also have increased frequencies of G 2 /M phase cells. In addition, CMPs and GMPs in which B-myb is disrupted in vitro proliferate more slowly. These results are consistent with previous reports documenting a role for B-myb in S/G 2 /M progression and checkpoint control (20, 22, 25, 46, 47) . A similar phenotype is also observed in the zebrafish crash&burn (crb) mutant (48) , which harbors a loss of function mutation in bmyb. Cells in these embryos have delays in mitotic progression, genomic instability, and increased cell death, and it is thought that loss of bmyb during S phase impairs CYCLIN B1 expression, which is required for progression through G 2 (48, 49) . Although we encountered difficulties in examining the cell cycle of LT-HSCs as a distinct population in B-myb KO mice due to their extremely low numbers, our data suggest that loss of Bmyb pushes HSCs out of quiescence, but arrests them in the S and G 2 /M phases. As loss of quiescence is associated with a failure to maintain long-term self-renewal (45) , these data provide a partial explanation for HSC depletion in these animals. B-myb KO LSK + cells express substantially higher levels of CCND1 mRNA, which, in complex with CDK4/6, drives the cell through G 1 and into S-phase (50) . It is interesting to note that differentiation of LT-HSCs into ST-HSCs and MPPs, but not HSC self-renewal, correlates with the induction of CCND1 mRNA (18) . As the CCND1 promoter is bound by B-MYB in ChIP assays (25) , this increase in cyclin D1 mRNA is likely due to the absence of repression of the CCND1 promoter by B-MYB. HSC differentiation is also accompanied by increases in CCNG2, whereas self-renewing HSCs do not exhibit such changes in gene expression (18) . CCNG2 is considered an atypical cyclin in that its up-regulation is associated with cell cycle inhibition, and studies have demonstrated the involvement of this gene in the induction and/or maintenance of cell cycle arrest (51) . CCNG2 mRNA levels in B-myb-deficient LSK + cells were decreased, and it is therefore possible that B-myb KO HSCs do enter the differentiation program but ultimately fail to complete it. It is interesting to note that even though the S and G 2 /M checkpoints in B-myb-null ESCs are defective, these cells still progress through the cell cycle, even with a loss of genomic integrity (20, 22) . Hence, defects in replication stress responses could also lead to abnormalities in HSC function and differentiation in the absence of B-myb expression.
Because multiple lineages are affected by the loss of B-myb, we also examined the level of cell death in the stem and progenitor compartments. We did not detect increases in the frequency of Annexin V + HSCs or MPPs; however, we did observe increased cell death in the three populations of myeloid progenitors, which would additionally contribute to the depletion of mature myeloid cells. As previously stated, despite the fact that B-myb KO mice have a profound reduction in the number of myeloid progenitors and mature myeloid cells, the percentage of GMPs in these animals is actually increased compared to controls. Accordingly, the level of ID1, which is normally upregulated as the cells transition from the LMPP to GMP stage (43) , is higher in B-myb-deficient LSK + cells. In addition, we observed higher levels of CEBPα and lower levels of GATA2 in B-myb KO LSK + cells. Previous studies have shown that GMP development is also favored if CEBPα is up-regulated before GATA2, and these cells will continue to give rise to neutrophils and monocytes if CEBPα expression is maintained (1) .
When viewed from the perspective of increased GMP frequency and its relation to pancytopenia, the B-myb KO phenotype is remarkably similar to that seen in patients with high-risk myelodisplastic syndrome (MDS) (52, 53) , a group of blood disorders that are characterized by cytopenias that arise due to ineffective hematopoiesis and often progress to acute meylogenous leukemia. MYBL2 is expressed at 20-30% of normal levels in CD34
+ cells of ∼65% of MDS cases, irrespective of karyotype (46, 54) . Consistent with the notion that partial loss of MYBL2 expression is associated with MDS, it has recently been shown that B-myb heterozygous mice develop MDS and other myeloproliferative neoplasms at 12-24 mo of age (54) . Although the hematopoietic compartment of younger animals did not show significant changes, the phenotype of a subset of the aged animals, particularly those were normalized to β-actin expression and are graphed as the average foldchange (±SEM). PCR reactions were performed in triplicate using cDNAs isolated from at least two independent pools of sorted cells per genotype.
subjected to transplant-induced replicative stress, is similar to that of B-myb KO mice immediately following pIpC administration. These data suggest that B-myb haploinsufficiency cooperates with other genetic lesions to cause disease, in contrast to that which occurs in the absence of B-myb expression or in cells expressing levels of B-myb that mirror those seen in CD34 + MDS cells (approximately 20-30% of normal) (46) . A better understanding of the role of B-myb in normal hematopoietic cell development will hopefully allow us to define its role in disease states that result in defective hematopoiesis, such as MDS.
Materials and Methods
Detailed information on animals, bone marrow transplantation, and flow cytometry can be found in SI Materials and Methods. Microarray and RT-PCR analysis were performed as described in SI Materials and Methods. Primer sequences are provided in SI Materials and Methods.
